Enterprise Therapeutics Secures £2.4M in Series A Financing

Enterprise TherapeuticsEnterprise Therapeutics, a Brighton, UK-based drug discovery company focused on new therapeutics for respiratory diseases, secured an additional £2.4m ($3.6m) in Series A financing.

The funds included £2m by new investor Imperial Innovations and £0.4m by founding investor Epidarex Capital, which brought the total Series A round to £4m.

The proceeds will consolidate and accelerate the drug discovery and target identification programs initiated by Enterprise Therapeutics earlier in 2015. The company is based at the Sussex Innovation Centre, University of Sussex.

Led by Martin Gosling, CSO, Enterprise Therapeutics is an early stage drug discovery company formed in May 2014 focusing on the discovery of novel disease modifying medications that target key drivers of respiratory disease pathology and progression in cystic fibrosis, chronic obstructive pulmonary disease (COPD) and severe asthma.






Join the discussion